In the humanized liver mouse model, the inflammatory effect of IL-6/GP130 pathway promoted hepatic lipid accumulation, suggesting the therapeutic potential of antagonizing GP130 signaling in the treatment of liver steatosis [57]. This evidence concerns the gene IL6 and fatty liver disease.